tarceva

Introduction to Tarceva

Tarceva, known generically as Erlotinib, is a targeted cancer therapy used primarily to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. It is classified as an epidermal growth factor receptor (EGFR) inhibitor, which functions by blocking the activity of a protein that signals cancer cells to grow and divide. Tarceva is usually prescribed for patients with specific genetic mutations in their cancer cells, making it a personalized treatment option. Its effectiveness in slowing cancer progression and extending survival times has made it a critical component in the oncology field.

Composition of Tarceva

The active ingredient in Tarceva is Erlotinib, present in a 100mg dosage. Erlotinib works by inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), which is often overexpressed in cancer cells. By blocking this receptor, Erlotinib effectively reduces the proliferation of cancer cells, thereby slowing the progression of the disease. This targeted action helps minimize damage to healthy cells, differentiating it from traditional chemotherapy.

Uses for Tarceva

• Treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations.
• Maintenance therapy for patients whose cancer has not progressed after initial chemotherapy.
• Treatment of locally advanced, unresectable, or metastatic pancreatic cancer in combination with gemcitabine.

Side Effects of Tarceva

• Rash and acne-like skin conditions.
• Diarrhea.
• Loss of appetite.
• Fatigue.
• Nausea and vomiting.
• Respiratory issues, such as cough or difficulty breathing.
• Liver function abnormalities.

Precautions of Tarceva

Before starting Tarceva, it is important to inform your healthcare provider about any existing health conditions, especially liver or kidney issues. Patients should avoid smoking, as it can decrease the effectiveness of the medication. Regular monitoring of liver function tests is recommended due to potential liver-related side effects. Pregnant or breastfeeding women should not use Tarceva, as it can harm the fetus or nursing infant. Patients should also be cautious when driving or operating machinery if they experience fatigue or vision changes.

Specifications of Tarceva

Tarceva is available in tablet form, specifically in 100mg and 150mg dosages. It is not available as an injection, syrup, or capsule. The tablets are typically taken orally once a day on an empty stomach, at least one hour before or two hours after eating.

Conclusion

Tarceva, with its active ingredient Erlotinib, offers a targeted approach to cancer treatment, primarily for non-small cell lung cancer and pancreatic cancer. By inhibiting EGFR, it effectively slows the progression of these cancers while minimizing damage to healthy cells. Patients should be aware of potential side effects and necessary precautions, and it is crucial to follow the healthcare provider’s instructions for optimal outcomes. Tarceva’s availability in tablet form provides a convenient option for many patients undergoing cancer treatment.